Free Trial

Focus Turns to MHRA/JCVI Press Conference at 1500BST/1000ET

UK
  • What could the UK MHRA/JCVI say at their press conference later today and what does that mean for the vaccine rollout?
  • In an interview this morning, a JCVI member suggested the Moderna vaccines could be put on reserve for younger members of the UK population, while the AstraZeneca vaccine is still used for older Britons, with blood clot risks seen as marginally higher among younger cohorts.
  • Channel 4 News sources earlier in the week also hinted that AstraZeneca rollout could be restricted to 30+ age range: there are "growing arguments to justify offering younger people — below the age of 30 at the very least — a different vaccine". This would be similar to decisions made in Germany & Netherlands in recent weeks.
  • More restricted use of the Astra vaccine could see supply become a greater issue for the UK, although PM Johnson this week has affirmed that, so far, the country remains on track to lift the next set of restrictions on April 12th.
  • It is unlikely we'll get a clean conclusion on whether there is a link between vaccination and blood clotting events. Scientists have already clarified that a dedicated study into the relationship would be required before coming to any conclusion.
MNI London Bureau | +44 203-865-3809 | edward.hardy@marketnews.com

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.